Dianthus Therapeutics DNTH First Development Program — Potential Milestone Payments Due
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Dianthus Therapeutics in its filing.
Tagged under the XBRL concept dnth:PotentialMilestonePaymentsDue.
The official record: Dianthus Therapeutics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Dianthus Therapeutics's first development program — potential milestone payments due.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Dianthus Therapeutics's first development program — potential milestone payments due?
- Dianthus Therapeutics (DNTH) reported first development program — potential milestone payments due of $4.1M in Q1 2026.
- How has Dianthus Therapeutics's first development program — potential milestone payments due changed year-over-year?
- Dianthus Therapeutics's first development program — potential milestone payments due increased by 2.5% year-over-year, from $4M to $4.1M.
- What does first development program — potential milestone payments due mean?
- This metric represents the total future financial obligations triggered by the achievement of specific clinical, regulatory, or commercial milestones associated with the company's lead drug development program. It serves as a key indicator of potential capital requirements and future cash outflows tied to the advancement of the primary pipeline asset. Monitoring these obligations is essential for assessing the company's long-term liquidity needs and the financial impact of successful product development.